CN102596937B - 作为蛋白激酶抑制剂的化合物和组合物 - Google Patents

作为蛋白激酶抑制剂的化合物和组合物 Download PDF

Info

Publication number
CN102596937B
CN102596937B CN201080038235.XA CN201080038235A CN102596937B CN 102596937 B CN102596937 B CN 102596937B CN 201080038235 A CN201080038235 A CN 201080038235A CN 102596937 B CN102596937 B CN 102596937B
Authority
CN
China
Prior art keywords
amino
pyrimidine
imidazoles
phenyl
cyclopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080038235.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN102596937A (zh
Inventor
A·Q·科斯塔勒斯
S·黄
J（X）·金
刘佐胜
S·佩基
D·蓬
J·泰卢
张琼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN102596937A publication Critical patent/CN102596937A/zh
Application granted granted Critical
Publication of CN102596937B publication Critical patent/CN102596937B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201080038235.XA 2009-08-28 2010-08-26 作为蛋白激酶抑制剂的化合物和组合物 Active CN102596937B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23808309P 2009-08-28 2009-08-28
US61/238,083 2009-08-28
US31306110P 2010-03-11 2010-03-11
US61/313,061 2010-03-11
PCT/EP2010/062495 WO2011023773A1 (en) 2009-08-28 2010-08-26 Compounds and compositions as protein kinase inhibitors

Publications (2)

Publication Number Publication Date
CN102596937A CN102596937A (zh) 2012-07-18
CN102596937B true CN102596937B (zh) 2014-02-12

Family

ID=42829939

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080038235.XA Active CN102596937B (zh) 2009-08-28 2010-08-26 作为蛋白激酶抑制剂的化合物和组合物

Country Status (19)

Country Link
US (3) US8242260B2 (OSRAM)
EP (1) EP2470528B1 (OSRAM)
JP (1) JP5726190B2 (OSRAM)
KR (1) KR101714107B1 (OSRAM)
CN (1) CN102596937B (OSRAM)
AR (1) AR077977A1 (OSRAM)
AU (1) AU2010288455B2 (OSRAM)
BR (1) BR112012004448A2 (OSRAM)
CA (1) CA2771673C (OSRAM)
EA (1) EA020479B1 (OSRAM)
ES (1) ES2527176T3 (OSRAM)
IN (1) IN2012DN00869A (OSRAM)
JO (1) JO3007B1 (OSRAM)
MX (1) MX2012002542A (OSRAM)
PL (1) PL2470528T3 (OSRAM)
PT (1) PT2470528E (OSRAM)
TW (1) TWI487701B (OSRAM)
UY (1) UY32859A (OSRAM)
WO (1) WO2011023773A1 (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
MX360932B (es) 2010-02-25 2018-11-21 Dana Farber Cancer Inst Inc Mutaciones del protooncogen de serina/treonina-proteina cinasa b-raf (braf) que confieren resistencia a los inhibidores del protooncogen de serina/treonina-proteina cinasa b-raf.
WO2013059634A1 (en) 2011-10-20 2013-04-25 The Regents Of The University Of California Use of cdk9 inhibitors to reduce cartilage degradation
CA2855243C (en) 2011-11-11 2020-04-14 Novartis Ag Method of treating a proliferative disease
RS58048B1 (sr) 2011-11-23 2019-02-28 Array Biopharma Inc Farmaceutske formulacije
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
US20150232452A1 (en) * 2012-09-19 2015-08-20 Ruga Corporation Novel raf kinase inhibitors
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
CA2912568A1 (en) * 2013-05-30 2014-12-04 Plexxikon Inc. Compounds for kinase modulation, and indications therefor
EP3013815B1 (en) 2013-06-25 2017-05-03 Bristol-Myers Squibb Company Carbazole carboxamide compounds useful as kinase inhibitors
AR096721A1 (es) 2013-06-25 2016-01-27 Bristol Myers Squibb Co Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos
JP2017506618A (ja) * 2013-08-28 2017-03-09 メディベイション テクノロジーズ， インコーポレイテッド 複素環式化合物および使用方法
GB2517988A (en) * 2013-09-09 2015-03-11 Redx Pharma Ltd Compounds
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
HK1243021A1 (zh) 2014-10-14 2018-07-06 The Regents Of The University Of California 使用cdk9和brd4抑制剂来抑制炎症
CN104402920B (zh) * 2014-11-27 2018-04-03 河南科技学院 一种合成2‑卤代‑3‑频那醇硼酸酯‑5‑氯苯胺的方法
ES2974991T3 (es) 2016-09-19 2024-07-02 Novartis Ag Combinaciones terapéuticas que comprenden un inhibidor de RAF y un inhibidor de ERK
WO2018146253A1 (en) 2017-02-10 2018-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
AU2018262891B2 (en) 2017-05-02 2021-04-01 Novartis Ag Combination therapy
WO2019133810A1 (en) 2017-12-28 2019-07-04 Tract Pharmaceuticals, Inc. Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
WO2020124397A1 (en) * 2018-12-19 2020-06-25 Inventisbio Shanghai Ltd. C-terminal src kinase inhibitors
AU2020276695A1 (en) 2019-05-13 2021-12-23 Novartis Ag New crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as Raf inhibitors for the treatment of cancer
WO2022036176A1 (en) * 2020-08-13 2022-02-17 Albert Einstein College Of Medicine N-cyclyl-sulfonamides useful for inhibiting raf
KR20240167846A (ko) 2022-03-28 2024-11-28 니캉 테라퓨틱스 인코포레이티드 사이클린 의존적 키나제 2 억제제로서의 설폰아미도 유도체
WO2023240024A1 (en) 2022-06-08 2023-12-14 Nikang Therapeutics, Inc. Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors
WO2025072462A1 (en) 2023-09-27 2025-04-03 Nikang Therapeutics, Inc. Sulfonamide derivatives as cyclin-dependent kinase 2 inhibitors

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2659739A (en) 1950-04-14 1953-11-17 Eastman Kodak Co 1-hydroxy-4-beta-cyanopropylamino-anthraquinone and process for preparing same
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6037136A (en) 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
GB2306108A (en) * 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
CA2256109A1 (en) 1996-05-23 1997-11-27 Applied Research Systems Ars Holding N.V. Compounds that inhibit the binding of raf-1 or 14-3-3 proteins to the beta chain of il-2 receptor, and pharmaceutical compositions containing same
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6204467B1 (en) 1998-03-24 2001-03-20 Ford Global Technologies, Inc. Method and apparatus for resistive welding
ME00275B (me) 1999-01-13 2011-02-10 Bayer Corp ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
AU2001285349A1 (en) 2000-08-30 2002-03-13 The Board Of Trustees Of The University Of Arkansas Induction of ldl receptor expression by extracellular-signal regulated kinase, erk-1/2
DOP2003000613A (es) 2002-03-13 2003-09-30 Array Biopharma Inc Derivados de bencimidazol n3 alquilado como inhibidores de mek (n3 alkylated benzimidazole derivatives as mek inhibitors)
US6644516B1 (en) 2002-11-06 2003-11-11 Continental Afa Dispensing Company Foaming liquid dispenser
JP2008531538A (ja) 2005-02-25 2008-08-14 クドス ファーマシューティカルズ リミテッド ２，４−ジアミノ−ピリドピリミジン誘導体とｍＴＯＲ阻害剤としてのその使用
AU2006217742A1 (en) 2005-02-25 2006-08-31 Kudos Pharmaceuticals Limited Hydrazinomethyl, HYDR zonomethyl and 5-membered heterocylic compounds which act as MTOR inhibitors and their use as anti cancer agents
JP5161102B2 (ja) 2005-11-22 2013-03-13 クドス ファーマシューティカルズ リミテッド ｍＴＯＲ阻害剤としてのピリドピリミジン、ピラゾピリミジンおよびピリミドピリミジン誘導体
BRPI0706395A2 (pt) 2006-01-11 2011-03-22 Astrazeneca Ab composto, uso do mesmo, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente e para tratar doença, composição farmacêutica, e, processo para preparar um composto
DK2057156T3 (en) 2006-08-23 2017-05-08 Kudos Pharm Ltd 2-METHYLMORPHOLINPYRIDO, PYRAZO AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS
TW200922582A (en) 2007-08-20 2009-06-01 Organon Nv N-benzyl, N'-arylcarbonylpiperazine derivatives
BRPI0908906A2 (pt) * 2008-03-21 2019-09-24 Novartis Ag compostos heterocíclicos e usos dos mesmos
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
CN102105459B (zh) * 2008-07-24 2014-09-10 内尔维阿诺医学科学有限公司 作为蛋白激酶抑制剂的3,4-二芳基吡唑类

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Dual binding site inhibitors of B-RAF kinase;Ronald L. Wolin, et al;《Bioorg. Med. Chem. Lett.》;20080404;第18卷;2825–2829 *
Ronald L. Wolin, et al.Dual binding site inhibitors of B-RAF kinase.《Bioorg. Med. Chem. Lett.》.2008,第18卷2825–2829.

Also Published As

Publication number Publication date
US8859548B2 (en) 2014-10-14
KR20120092577A (ko) 2012-08-21
BR112012004448A2 (pt) 2017-05-30
JP5726190B2 (ja) 2015-05-27
US20110052578A1 (en) 2011-03-03
AU2010288455A1 (en) 2012-02-23
AU2010288455B2 (en) 2013-01-31
WO2011023773A1 (en) 2011-03-03
US20140011825A1 (en) 2014-01-09
PT2470528E (pt) 2014-12-29
AR077977A1 (es) 2011-10-05
US8242260B2 (en) 2012-08-14
MX2012002542A (es) 2012-04-02
CA2771673A1 (en) 2011-03-03
KR101714107B1 (ko) 2017-03-08
UY32859A (es) 2011-03-31
TWI487701B (zh) 2015-06-11
PL2470528T3 (pl) 2015-03-31
JO3007B1 (ar) 2016-09-05
CA2771673C (en) 2016-07-12
ES2527176T3 (es) 2015-01-21
EP2470528A1 (en) 2012-07-04
IN2012DN00869A (OSRAM) 2015-07-10
CN102596937A (zh) 2012-07-18
US8563553B2 (en) 2013-10-22
EA020479B1 (ru) 2014-11-28
TW201111365A (en) 2011-04-01
EA201200323A1 (ru) 2012-09-28
EP2470528B1 (en) 2014-10-01
US20120225899A1 (en) 2012-09-06
JP2013503139A (ja) 2013-01-31

Similar Documents

Publication Publication Date Title
CN102596937B (zh) 作为蛋白激酶抑制剂的化合物和组合物
TWI855000B (zh) Ｓｔｉｎｇ促效化合物
CN101001857B (zh) 2-(吡啶-2-基氨基)-吡啶并[2,3-d]嘧啶-7-酮
JP2020143131A (ja) Ｅｇｆｒモジュレーターとしての置換２−アミノピリミジン誘導体
US9532987B2 (en) Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
CN102428084A (zh) 化合物
CN103080107A (zh) 作为蛋白激酶抑制剂的杂芳基化合物和组合物
CN102971306A (zh) 作为激酶lrrk2的抑制剂的吡唑并吡啶
EP3004110A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
EA010596B1 (ru) Замещённые пирролопиразольные производные в качестве ингибиторов киназы
JP2006513208A5 (OSRAM)
CN107188898B (zh) 制备噻吩并嘧啶化合物的方法
JP2018509442A (ja) Ｆｇｆｒ４阻害剤としてのホルミル化ｎ−複素環式誘導体
JP2007509995A (ja) 可溶性グアニル酸シクラーゼの刺激剤および脂質低下物質を含有する新規組合せ物
CN112189009B (zh) 作为tcr-nck相互作用的抑制剂的色烯衍生物
MX2015000797A (es) Uso de inhibidores de vegfr-3 para tratar carcinoma hepatocelular.
CN103459396B (zh) 作为c-Met酪氨酸激酶抑制剂的[1,2,4]三唑并[4,3-b]哒嗪化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent for invention or patent application
CB02 Change of applicant information

Address after: Basel

Applicant after: Novartis Ag

Address before: Basel

Applicant before: Novartis AG

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: NOVARTIS AG TO: NOVARTIS CO., LTD.

C14 Grant of patent or utility model
GR01 Patent grant